(Press-News.org) VIDEO:
An international clinical trial led by Dr. Brian Feagan of Western University in London, Canada has found that the investigational antibody vedolizumab is an effective treatment for those suffering from...
Click here for more information.
An international clinical trial led by Dr. Brian Feagan of Western University in London, Canada, has found that the investigational antibody vedolizumab is an effective treatment for those suffering from ulcerative colitis (UC) and Crohn's disease (CD) when other treatments have failed. The results of the study called GEMINI are published in the August 22 issue of the New England Journal of Medicine.
Chronic and debilitating diseases, CD and UC are the two most common forms of inflammatory bowel disease and affect more than four million people worldwide. Symptoms may include bleeding, diarrhea, fatigue, weight loss and anemia.
"The publication of these study findings are important since the results support the potential for vedolizumab, if approved, to help manage symptoms in some patients for whom previous treatments have failed," said Dr. Brian Feagan, professor of medicine, and epidemiology and biostatistics at Western's Schulich School of Medicine & Dentistry and director of Robarts Clinical Trials at the Robarts Research Institute. "The data from the GEMINI program suggest that vedolizumab may provide people living with CD and UC an additional option for inducing and maintaining clinical remission."
Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan and a global leader in the industry, funded the trial and has applied to the U.S. Food and Drug Administration and the European Medicines Agency to have vedolizumab licensed for the treatment of adults with moderately to severely active CD and UC.
The GEMINI studies are the culmination of 15 years of work. The molecule involved was initially developed by a London (Canada) scientist, Andrew Lazorovits, doing post-doctoral studies in Boston. He died before seeing his discovery go to clinical trial.
There are four parts to the GEMINI studies, involving 2,700 patients in 40 countries. Both Phase 3 trials, GEMINI I studied patients with UC and GEMINI II focused on patients with CD. Those studies found patient outcomes with the new drug were superior compared to placebo.
"I think the most exciting part of it is, this molecule has the potential to be something quite different than our existing therapies. CD and UC are chronic inflammatory diseases, conditions of the immune system which have a dis-regulated immune response presumably to the bacteria in the bowel. And we don't really know the cause of that dis-regulated response, and so we're forced to treat that with potent immunosuppressant anti-inflammatory drugs. These drugs have side effects because they're broad spectrum. They affect inflammation in the gut which we want them to do, but they also affect other places such as the lungs, the skin and the brain where we don't want to suppress the immune system. The consequence of that broad spectrum activity can be side effects such as pneumonia, skin infections or blood infections," explains Dr. Feagan. "Vedolizumab interferes with trafficking of white blood cells into the gut specifically, as opposed to other places in the body. It has the potential advantage of selective suppression of the immune system and perhaps avoiding the side effects which are a major detriment to patient care."
### END
Studies show vedolizumab is an effective treatment for Crohn's disease and ulcerative colitis
2013-08-22
ELSE PRESS RELEASES FROM THIS DATE:
Family history of diabetes increases the risk of prediabetes by 26 percent, with effect most evident in non-obese
2013-08-22
A study involving more than 8,000 participants has shown that people with a family history of diabetes see their risk of prediabetes increase by 26%. The research is published in Diabetologia, the journal of the European Association for the Study of Diabetes, and is by Dr Andreas Fritsche and colleagues from the German Center for Diabetes Research*.
Prediabetes is a condition most often described as the 'state between normal blood sugar control and full diabetes', and indeed prediabetes progresses to full blown diabetes in up to 20% of individuals affected per year. ...
Breast is best: Good bacteria arrive from mum's gut via breast milk
2013-08-22
Scientists have discovered that important 'good' bacteria arrive in babies' digestive systems from their mother's gut via breast milk.
Although this does confirm that when it comes to early establishment of gut and immune health, 'breast is best', a greater understanding of how babies acquire a population of good bacteria can also help to develop formula milk that more closely mimics nature.
The study, published today (22 August) in Environmental Microbiology, which is a journal of the Society for Applied Microbiology (SfAM), was led by Professor Christophe Lacroix ...
New health economics study highlights societal benefits of knee replacement surgery
2013-08-22
Rosemont, Ill. – The full impact of knee replacement surgery on both patients' lives and on society includes significant overall cost savings, according to a new study published in the Journal of Bone and Joint Surgery (JBJS). Researchers found that for the average patient undergoing knee replacement surgery, the expense of surgery is offset by indirect savings of nearly $40,000. This translates to an average lifetime societal benefit of $10,000-$30,000. Most of the societal savings come from the patient's ability to maintain employment and increase earnings over a longer ...
Pazopanib shows better quality-of-life in advanced kidney cancer
2013-08-22
BOSTON -- Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.
Pazopanib (Votrient) and sunitinib (Sutent), both recently approved as first-line treatments for advanced renal cell cancer, had similar benefits in delaying progression of the disease, but the safety profile and many measures of quality of life favored pazopanib, suggesting a potential shift in standard of care in metastatic ...
Study finds mother's genes can impact aging process
2013-08-22
As we age, our cells change and become damaged. Now, researchers at Karolinska Institutet and the Max Planck Institute for Biology of Aging have shown that aging is determined not only by the accumulation of changes during our lifetime but also by the genes we acquire from our mothers. The results of the study are published in the journal Nature.
There are many causes of aging that are determined by an accumulation of various kinds of changes that impair the function of bodily organs. Of particular importance in aging, however, seems to be the changes that occur in the ...
A brighter method for measuring the surface gravity of distant stars
2013-08-22
Astronomers have found a clever new way to slice and dice the flickering light from a distant star in a way that reveals the strength of gravity at its surface.
That is important because a star's surface gravity is one of the key properties that astronomers use to calculate a star's physical properties and assess its evolutionary state.
The new technique can also be used to significantly improve estimates of the sizes of the hundreds of exoplanets that have been discovered in the last 20 years. Current estimates have uncertainties ranging from 50 percent to 200 percent. ...
New results from Daya Bay
2013-08-22
The international Daya Bay Collaboration has announced new results about the transformations of neutrinos - elusive, ghostlike particles that carry invaluable clues about the makeup of the early universe. The latest findings include the collaboration's first data on how neutrino oscillation – in which neutrinos mix and change into other "flavors," or types, as they travel – varies with neutrino energy, allowing the measurement of a key difference in neutrino masses known as "mass splitting."
"Understanding the subtle details of neutrino oscillations and other properties ...
Berlin researchers open a door for solid state physics
2013-08-22
Without the currently available plethora of X-ray methods, basic research in the physical sciences would be unthinkable. The methods are used in solid state physics, in the analysis of biological structures, and even art historians have X-rays to thank for many new insights. Now, scientists at the Helmholtz Center Berlin (HZB) have identified yet another area of application. The team around Dr. Martin Beye and Prof. Alexander Föhlisch was able to show that solids lend themselves to X-ray analysis based on nonlinear physical effects. Until now, this could only be done using ...
Warming Antarctic seas likely to impact on krill habitats
2013-08-22
Antarctic krill are usually less than 6 cm in length but their size belies the major role they play in sustaining much of the life in the Southern Ocean. They are the primary food source for many species of whales, seals, penguins and fish.
Krill are known to be sensitive to sea temperature, especially in the areas where they grow as adults. This has prompted scientists to try to understand how they might respond to the effects of further climate change.
Using statistical models, a team of researchers from the British Antarctic Survey and Plymouth Marine Laboratory assessed ...
Researchers reveal hunter-gatherers' taste for spice
2013-08-22
Our early ancestors had a taste for spicy food, new research led by the University of York has revealed.
Archaeologists at York, working with colleagues in Denmark, Germany and Spain, have found evidence of the use of spices in cuisine at the transition to agriculture. The researchers discovered traces of garlic mustard on the charred remains of pottery dating back nearly 7,000 years.
The silicate remains of garlic mustard (Alliaria petiolata) along with animal and fish residues were discovered through microfossil analysis of carbonised food deposits from pots found at ...